Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

A cyberattack on Synnovis has been linked to a patient's death at King's College Hospital, marking a serious hacking ...